PI3K/AKT/mTOR alterations were detected in 29.8% of samples, with expectedly high frequencies in breast (49.4%) and gynecologic (endometrial, 80.7%; cervix, 54.7%; and gynecologic, 89.4%) cancers. Here, MTOR is linked to cancer.